Latest Ratios: P/E Ratio 22.0x · EV/EBITDA 17.2x · ROE 26.6%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $189M | $147M | $70M | $69M | $60M | $120M | $73M | $56M | $29M | $25M | $23M |
| Enterprise Value | $205M | $163M | $81M | $81M | $75M | $135M | $73M | $53M | $24M | $21M | $21M |
| P/E Ratio → | 22.05 | 16.34 | 32.73 | 9.79 | 13.18 | 27.04 | 11.88 | 13.38 | 17.97 | 4.92 | 27.80 |
| P/S Ratio | 2.83 | 2.20 | 1.30 | 1.51 | 1.43 | 2.86 | 2.09 | 2.05 | 1.29 | 1.14 | 1.15 |
| P/B Ratio | 5.40 | 4.00 | 2.27 | 2.20 | 2.36 | 4.73 | 3.81 | 3.28 | 1.67 | 1.83 | 2.61 |
| P/FCF | — | — | 13.45 | 15.48 | — | — | 13.63 | 28.94 | 13.36 | 9.66 | 177.14 |
| P/OCF | — | — | 11.31 | 12.72 | — | — | 12.32 | 16.77 | 9.33 | 7.75 | 49.80 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.45 | 1.51 | 1.76 | 1.79 | 3.22 | 2.10 | 1.94 | 1.06 | 0.96 | 1.04 |
| EV / EBITDA | 17.18 | 13.65 | 9.73 | 12.29 | 12.85 | 23.15 | 9.54 | 9.68 | 8.05 | 6.38 | 18.59 |
| EV / EBIT | 19.17 | 12.64 | 25.39 | 8.16 | 12.20 | 21.99 | 9.00 | 10.54 | 6.97 | 7.37 | 18.01 |
| EV / FCF | — | — | 15.54 | 18.12 | — | — | 13.74 | 27.29 | 10.98 | 8.08 | 160.18 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 29.3% | 29.3% | 27.0% | 27.7% | 31.2% | 31.2% | 37.7% | 36.0% | 35.4% | 32.7% | 26.8% |
| Operating Margin | 16.1% | 16.1% | 13.3% | 12.5% | 12.2% | 12.2% | 20.3% | 18.4% | 10.6% | 12.5% | 2.6% |
| Net Profit Margin | 13.5% | 13.5% | 4.0% | 15.3% | 10.9% | 10.9% | 17.5% | 15.3% | 7.2% | 23.2% | 4.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 26.6% | 26.6% | 6.8% | 24.8% | 18.0% | 20.6% | 33.9% | 24.2% | 10.5% | 45.0% | 9.5% |
| ROA | 15.8% | 15.8% | 4.1% | 14.0% | 9.3% | 11.4% | 21.6% | 18.3% | 8.9% | 37.0% | 6.9% |
| ROIC | 17.0% | 17.0% | 12.6% | 10.3% | 9.5% | 12.8% | 31.7% | 28.9% | 16.5% | 25.2% | 5.4% |
| ROCE | 24.8% | 24.8% | 17.6% | 14.4% | 13.6% | 16.1% | 30.0% | 25.9% | 15.4% | 23.9% | 5.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.45 | 0.45 | 0.44 | 0.47 | 0.63 | 0.63 | 0.37 | 0.27 | 0.00 | 0.01 | 0.01 |
| Debt / EBITDA | 1.39 | 1.39 | 1.63 | 2.23 | 2.73 | 2.73 | 0.91 | 0.84 | 0.01 | 0.04 | 0.06 |
| Net Debt / Equity | — | 0.44 | 0.35 | 0.38 | 0.59 | 0.59 | 0.03 | -0.19 | -0.30 | -0.30 | -0.25 |
| Net Debt / EBITDA | 1.35 | 1.35 | 1.31 | 1.79 | 2.58 | 2.58 | 0.08 | -0.59 | -1.75 | -1.24 | -1.97 |
| Debt / FCF | — | — | 2.09 | 2.64 | — | — | 0.11 | -1.65 | -2.38 | -1.57 | -16.96 |
| Interest Coverage | 15.55 | 15.55 | 5.72 | 18.69 | 13.27 | 17.49 | 34.48 | 22.69 | 486.43 | 237.25 | 31.49 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.23 | 3.23 | 2.84 | 3.20 | 2.74 | 2.74 | 4.34 | 5.10 | 6.40 | 4.62 | 4.44 |
| Quick Ratio | 1.71 | 1.71 | 1.66 | 1.53 | 1.63 | 1.63 | 2.76 | 3.64 | 4.67 | 3.42 | 2.72 |
| Cash Ratio | 0.49 | 0.49 | 0.53 | 0.42 | 0.14 | 0.14 | 1.72 | 2.43 | 2.92 | 1.91 | 1.10 |
| Asset Turnover | — | 1.09 | 1.03 | 0.89 | 0.86 | 0.86 | 1.12 | 1.06 | 1.13 | 1.34 | 1.81 |
| Inventory Turnover | 2.12 | 2.12 | 2.57 | 2.06 | 2.28 | 2.28 | 2.63 | 2.79 | 3.31 | 4.78 | 4.13 |
| Days Sales Outstanding | — | 95.86 | 94.14 | 78.82 | 133.56 | 133.56 | 54.02 | 55.08 | 67.12 | 60.28 | 53.94 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 0.0% | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | 0.6% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.5% | 6.1% | 3.1% | 10.2% | 7.6% | 3.7% | 8.4% | 7.5% | 5.6% | 20.3% | 3.6% |
| FCF Yield | — | — | 7.4% | 6.5% | — | — | 7.3% | 3.5% | 7.5% | 10.4% | 0.6% |
| Buyback Yield | 1.9% | 2.4% | 5.0% | 2.2% | 2.7% | 4.6% | 4.7% | 7.1% | 0.8% | 1.2% | 2.0% |
| Total Shareholder Yield | 1.9% | 2.4% | 5.0% | 2.2% | 2.7% | 4.6% | 4.7% | 7.2% | 0.8% | 1.2% | 2.0% |
| Shares Outstanding | — | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M |
Extreme customer concentration risk
According to current market data, PDEX trades at a trailing P/E of 23.02, which appears to bake in aggressive growth expectations that may be difficult to sustain given the company's historical volatility and reliance on a concentrated set of OEM partners for its surgical instrument revenue.
The forward P/E of 15.60 suggests that the market anticipates a significant earnings expansion, yet this valuation premium warrants caution when compared to the company's inconsistent free cash flow generation. Investors should monitor whether the current multiple is supported by genuine operational scaling or if it reflects a temporary optimism regarding the company's niche position in the medical device supply chain.
Based on reported figures, PDEX has struggled to consistently compound returns, with ROIC fluctuating between 1.3% and 5.5% over the last ten quarters, suggesting that the company's capital-intensive manufacturing model often fails to generate returns that meaningfully exceed its cost of capital in the long term.
The observed trend in ROIC indicates that while the company is expanding its footprint, the underlying efficiency of its invested capital remains constrained by the high costs of precision manufacturing. This performance suggests that management's ability to drive shareholder value is highly sensitive to the timing of large-scale OEM project completions rather than steady, organic compounding.
As reported in recent financial statements, the company's cash conversion cycle remains elevated, peaking at 215 days in 2026Q2, which highlights a structural inefficiency in managing inventory and receivables that directly impacts the firm's ability to maintain a stable cash buffer for operational contingencies.
The persistent length of the cash conversion cycle, driven largely by high days inventory outstanding, suggests that PDEX is carrying significant capital in the form of specialized components. This inventory dependence appears to be a byproduct of the OEM-centric model, where the company must hold stock to meet the unpredictable delivery schedules of its primary medical partners.
Based on the 2026Q3 balance sheet, the company's liquidity position appears vulnerable, as historical data shows a tendency for cash balances to drop to near-zero levels, such as the $419,000 reported in 2025Q4, despite the company's ongoing need to fund working capital for large OEM contracts.
While the current ratio of 3.67 suggests a healthy cushion on paper, the actual cash availability is often obscured by the high proportion of current assets tied up in inventory and receivables. Investors should monitor the company's ability to convert these assets into cash, as any delay in OEM payments could rapidly stress the firm's operational flexibility.
The most commonly misapplied metric for PDEX is the standard P/E ratio, which obscures the company's underlying earnings volatility and the lumpy nature of its engineering services revenue, leading investors to potentially overvalue the firm during periods of temporary margin expansion.
Because PDEX operates as a specialized OEM partner, its earnings are heavily influenced by the timing of regulatory milestones and product launches rather than steady-state demand. Analysts should instead focus on EV/EBITDA or free cash flow yield, which better account for the company's capital structure and the significant working capital requirements inherent in its manufacturing model.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PDEX stock.
Pro-Dex, Inc.'s current P/E ratio is 22.0x. The historical average is 22.8x. This places it at the 62th percentile of its historical range.
Pro-Dex, Inc.'s current EV/EBITDA is 17.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 11.7x.
Pro-Dex, Inc.'s return on equity (ROE) is 26.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 5.1%.
Based on historical data, Pro-Dex, Inc. is trading at a P/E of 22.0x. This is at the 62th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Pro-Dex, Inc. has 29.3% gross margin and 16.1% operating margin. Operating margin between 10-20% is typical for established companies.
Pro-Dex, Inc.'s Debt/EBITDA ratio is 1.4x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.